Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients

Seminars in Liver Disease

Volumn 19, Issue 1 SUPPL. 1, 1999, Pages 77-86

  Neary, Maureen P ^a   Cort, Susannah ^a   Bayliss, Martha S ^b   Ware Jr , John E ^b,c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b QualityMetric Incorporated   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

Health related quality of life; Hepatitis quality of life questionnaire; SF 36; Sustained virologic response

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRESS SYNDROME; FEMALE; HEPATITIS C; HUMAN; MALE; MENTAL HEALTH; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RETREATMENT; REVIEW; SLEEP; SOCIAL INTERACTION; SOMNOLENCE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0032922191     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Conry-Cantilena C, Vanraden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691-1696
2. Merican I, Sherlock S, McIntyre N, Dusheiko GM. Clinical, biochemical and histological features in 102 patients with chronic hepatitis C virus infection. Q J Med 1993;86:119-125
3. Ware JE, Snow KK, Kosinski M, Gandek B, eds. SF-36 Health Survey Manual and Interpretation Guide. Boston, Mass: New England Medical Center and The Health Institute; 1993
4. Wachtel T, Piette J, Mor V, Stein M, Fleishman J, Carpenter C. Quality of life in persons with human immunodeficiency virus infection: measurement by the Medical Outcomes Study instrument. Ann Intern Med 1992;116:129-137
5. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209-211
6. Bayliss MS, Gandek B, Bungay KM, Sugano D, Hsu MA, Ware JE Jr. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998;7:39-55
7. Bayliss MS, Carithers RL, Hoofnagle JH, et al. Outcomes in chronic hepatitis C: clinical features, symptoms, and health-related quality of life. Hepatology Submitted
8. Davis GL, Balart LA, Schiff ER, et al. Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. Clin Ther 1994;16:334-343
9. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999;29:264-270
10. Davis GL, Estehan-Mur R, Rustgi V, et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-1499
11. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492
12. Poynard T, Marcellin P, Lee S, et al. Randomised trial of interferon alfa-2b and ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432
13. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435
14. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40-66
15. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992;305:160-164
16. Katz JN, Larson MG, Phillips CB, Fossel AH, Liang MH. Comparative measurement sensitivity of short and longer health status instruments. Med Care 1992;30:917-925
17. Phillips RC, Lansky DJ. Outcomes management in heart valve replacement surgery: early experience. J Heart Valve Dis 1992;1:42-50
18. Ware JE, Bayliss MS, Mannochia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. Hepatology Submitted
19. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic-hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-1506
20. Reichard O, Foberg U, Fryden A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks. Hepatology 1994;19:280-285
21. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-789
22. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-881